Cardiovascular disease is the leading cause of morbidity and mortality in maintenance hemodialysis (MHD) patients. [1] [2] [3] Evaluation of cardiac function by measurement of key cardiovascular variables such as heart rate, blood pressure, cardiac output (CO), and total peripheral resistance (TPR) is of particular interest in this patient cohort.
Cardiovascular disease is the leading cause of morbidity and mortality in maintenance hemodialysis (MHD) patients. [1] [2] [3] Evaluation of cardiac function by measurement of key cardiovascular variables such as heart rate, blood pressure, cardiac output (CO), and total peripheral resistance (TPR) is of particular interest in this patient cohort.
Since invasive techniques, such as dye-dilution or thermodilution, are not practical in outpatient settings, a pressing need exists for an easy, noninvasive and continuous (i.e., throughout a whole dialysis treatment) assessment of cardiac function. 4 The Transonic (TRS, Transonic Systems, Ithaca, NY, USA) device is a validated and widely used method for the assessment of CO in MHD patients. The TRS system uses an ultrasound indicator dilution technique, [5] [6] [7] requiring the injection of 0.9% sodium chloride solution. The method is noncontinuous, and typically one to two CO measurements per dialysis session are performed. Because of the need to inject an indicator (0.9% saline), the method is not entirely noninvasive.
Impedance cardiography (ICG) has been shown to be a useful tool for noninvasive continuous CO measurements. 8 -10 Recently, the Task Force Monitor (TFM; CN Systems, Austria) has gained increased attention for the continuous beatto-beat assessment of several cardiovascular variables, among them stroke volume and CO. Furthermore, the TFM measures beat-to-beat systolic, diastolic, and mean arterial blood pressure (BP) by the vascular unloading technique and has the capability to assess baroreceptor sensitivity and to perform spectral analysis of heart rate and blood pressure variability. 11 Although the TFM is frequently used in cardiology and intensive care settings, nothing has been reported about the feasibility of the technique in MHD patients so far. [12] [13] [14] This study compares CO measurements by TFM and TRS in MHD patients.
Methods
Patients on standard thrice-weekly MHD with arteriovenous fistula as vascular access and an access recirculation of Ͻ4% were enrolled after obtaining their written informed consent. The study was approved by the Institutional Review Board at the Beth Israel Medical Center, New York.
Cardiac output was measured simultaneously with both devices in supine patients after 1, 2, and 3 hours on dialysis. Each measurement took approximately 1 minute. This is the time needed by the TRS device to report the CO. The mean of the beat-to-beat COs provided by the TFM was recorded. On average, five CO measurements per patient were obtained (minimum 3, maximum 7; in total 61 measurements). The mean CO per dialysis session for each subject was used for further statistical analyses. By design, each patient was in the supine position for at least 60 minutes before the first measurement started.
Task Force Monitor Measurements
Impedance cardiography measures intrathoracic fluid shifts during a cardiac cycle. Task Force Monitor electrodes were attached to the patient as described elsewhere. 15 
where H is the body height. Cardiac output is calculated as the product of SV and heart rate (HR)
The crucial element of CO measurements with ICG is to obtain a good estimate for V th . Hence, Sramek et al. estimate V th by modeling the thorax as a truncated cone or frustum, respectively. 15 Underweight people are expected to have a more cylindrical thorax shape, whereas the obese will have a more frustum-shaped thorax. In a new aspect of estimating V th , the influence of body composition (by body mass index; BMI), as well as of the base impedance Z 0 is considered
where the scaling factor C 1 and the powers n and m are subject to proprietary nondisclosure. 15 
Transonic System Measurements
Cardiac output measurement with TRS requires the injection of a 10-mL bolus of isotonic saline into the venous line as an indicator substance. After the passage through heart and lungs, the arterial line indicator concentration curve is recorded. Cardiac output, which is inversely proportional to the concentration of the indicator sampled downstream, is then automatically computed from the area of the concentration curve according to the following equation (StewartHamilton equation): (5) with V V being the quantity of the indicator [mL], C the indicator concentration, and t the time.
Statistical Analyses
Continuous data are presented as mean Ϯ standard deviation (SD) and range. Cardiac output measurements by TFM and TRS were compared by means of Bland-Altman and Pearson regression analysis. The mean difference between both methods for CO measurements was tested against the a priori defined value of 0 mL/min by the one-sample t test. A twosided p value Ͻ0.05 was considered significant. All statistical analyses were performed with the SPSS version 11.5 (SPSS Inc., Chicago, IL).
Results
The baseline characteristics of the study population are shown in Table 1 . In the 12 patients studied, mean CO with TRS was 5.4 L/min (SD ϭ 1.1 L/min) and 5.0 L/min with TFM (SD ϭ 0.8 L/min).
Comparison Between TRS and TFM
Linear regression analysis showed good correlation between both techniques (Figure 1 ; r ϭ 0.802, R 2 ϭ 0.64, p ϭ 0.002). Bland-Altman analysis (Figure 2 ) revealed no systematical difference for CO measurements between the two methods. The mean difference for the CO measurements between the two methods (0.4 L/min) was not significantly different from zero (95% CI: -0.01 to 0.8; SD: 0.6; p Ͼ 0.05).
Group Comparison
The study population was dichotomized by using the cohort's median of the average of CO measurements (5.2 L/min) for both techniques. For patients with CO below the cohort's median, the mean difference for CO measurements between the two methods (0.01 L/min) was not significantly different from zero (95% CI: Ϫ0.3 to 0.3; SD: 0.8; p ϭ 0.963), whereas for patients above the cohorts median, the mean difference between the two techniques was significantly different from zero (95% CI: 0.4 to 1.1; SD: 1; p Ͻ 0.001).
Within-Patient Variability
The SD of the differences between single CO values and the respective subject's mean CO did not differ significantly be- n ϭ 12; values are mean Ϯ SD/percent or range. * The dose of dialysis is generally defined as the total urea removal provided during each treatment (dialyzer urea clearance /K/ ϫ treatment time /t/) divided by the urea distribution volume (V) derived from urea kinetic modeling. eKt/V (e for equilibrated) reflects the dose calculated from the postdialysis blood urea nitrogen after rebound of nitrogen into the blood compartment has occurred; d indicates that urea clearance achieved with the individual dialysis treatment is taken into account, and r indicates that the individual residual renal function is taken into account.
† The equilibrated normalized protein catabolic rate is used to assess dietary protein intake in patients who are in steady state (in grams per kilogram body weight per day).
tween the two methods (p Ͼ 0.05) with 0.8 L/min (TRS) and 0.5 L/min (TFM), respectively (Figure 3, A and B) .
Discussion
The main finding of this study is that absolute CO measurement and reproducibility by TFM and TRS do not differ significantly. CO assessment by the TRS system is well established in dialysis patients and is based on the well-explored theory of tracer dilution techniques (Stewart-Hamilton equation). [5] [6] [7] It can be easily performed by a nurse and has a low potential for side effects, although it cannot be considered as completely noninvasive. However, this method lacks the possibility of continuous (i.e., throughout a whole dialysis session) monitoring of cardiovascular variables (e.g., CO, CI, TPR, and BP). The strength of the TFM is the capability to assess CO (and other key cardiovascular variables) on a continuous, noninvasive beat-to-beat basis without the need of indicator injection or permanent nurse attendance. A shortcoming of the TFM is the fact that theoretical foundations of bioimpedance and ICG still need to be refined for further improvement of the results. Nevertheless, CO measurements with ICG have already been shown to be closely related with echocardiographic measurements in MHD patients and useful for estimation of individual hemodynamic changes during the dialysis procedure. 9, 16 Furthermore, Wynne et al. demonstrated that ICG variables correlate significantly with the amount of fluid removed during a hemodialysis session. 17 This feature is of special interest, since an ultrafiltration rate Ͼ10 mL/h per kilogram body weight was found to be associated with higher odds of intradialytic hypotension and a higher risk of mortality in the Dialysis Outcome and Practice Patterns Study. 18 Many underlying causes are known for the development of intradialytic blood pressure drops, such as autonomic neurop- athy (resulting in an inadequate increase of arteriolar tone during ultrafiltration), impaired baroreceptor sensitivity, cardiac systolic or diastolic dysfunction, or reduced stroke volume resulting from a mismatch between ultrafiltration rate and plasma refilling rate; yet the underlying pathophysiology behind is not completely understood. 19 -24 Yoshii et al. suggested that a reduction in parasympathetic activity next to sympathetic nerve activation and a pronounced increase in TPR are responsible mechanisms for maintaining blood pressure in patients on MHD. 25 Due to its capability to measure SV, HR, CO, CI, BP, and TPR continuously, online monitoring of cardiovascular variables by TFM is a promising tool to further elucidate the pathophysiology of intradialytic hypotension.
Admittedly, there are shortcomings to our study. No differences between the two methods were discerned; however, this may be due to the small sample size of the study population (n ϭ 12). This is especially true given the relatively large measurement error and poor resolution (0.5 L/min) for indicator dilution technique. Furthermore, it would be interesting to see how ICG accuracy varies as a function of CO. Although our study was not specifically designed to elucidate this issue, it is important to note that the difference between the two methods increases with higher CO. However, since none of the two methods can be considered the gold-standard, we cannot tell whether TRS overestimates or if TFM underestimates CO. The use of an invasive method for CO determination would be most useful to further explore that point, but potentially severe complications argue against such an approach.
Another method that allows good estimation of CO is echocardiography; however, it is a highly operator-dependent method and particularly difficult to reproduce during hemodialysis. Moreover, a simultaneous determination of CO by echocardiography and ICG is problematic, because of the bioimpedance electrodes in place.
In view of the fact that body composition influences the calculation of V th (Equation 4), which is a vital information for SV calculation, a broad range of BMIs (from 19.5 to 31.4) has been included in the present study. Thus, the method seems to be established within the above range of BMIs but at present it cannot be recommended in patients outside the studied BMI range. More basic research in the field of ICG is needed, particularly the study of the hemodynamics in subjects with very low and high BMIs, given that MHD patients with a low BMI have a worse clinical outcome as compared with their more obese or more muscular fellow patients. 26 -29 In addition, the formula by Sramek et al. assumes that in a large normal adult population, the averaged linear distance between the electrodes is 17% of total body height, in that way eliminating the need for length measurements. 10, 15 Since this information is also used for the calculation of the electrical participating thoracic volume (V th ; Equation 2) needed for SV calculation, the assumption by Sramek et al. may be violated in patients at the extremes of body size, and further studies in these patient groups are needed.
Another important point to consider is the fact that key parameters needed to compute CO by impedance cardiography are based on data obtained in healthy subjects with normal hydration status. Hemodialysis patients are characteristically overhydrated and undergo rapid "correction" by ultrafiltration during dialysis. Our study was not designed to explore the effect of interdialytic weight gain and ultrafiltration rate on CO. Moreover, a study of the variation of CO measurements in a group of elderly, wasted, and ethnically diverse patients is also needed to further evaluate the bioimpedance-based TFM technology.
In conclusion, the TFM is a practical noninvasive device for the continuous beat-to-beat monitoring of cardiovascular variables in MHD patients. In addition, it might be a promising technique to shed light on the underlying pathophysiological mechanisms of intradialytic hemodynamic events.
